Disclaimer: This site aggregates publicly available data from official government sources (FDA, ClinicalTrials.gov, PubMed, SEC EDGAR) for general reference only. It does NOT constitute medical advice, diagnosis, treatment recommendations, or investment advice.

Clinical Trial

The Efficacy and Safety of Transcutaneous Auricular Vagus Nerve Stimulation for Depression in PD

NCT: NCT07679529 · NOT_YET_RECRUITING

NCT IDNCT07679529
StatusNOT_YET_RECRUITING
Start Date2026-07-01
Completion2026-08-01
SponsorThe First Affiliated Hospital with Nanjing Medical University (OTHER)
First posted
Last updated

Brief Summary

This study is a double blind comparative study examining the effectiveness of the transcutaneous auricular vagus nerve stimulation treatment on Parkinson's disease patients with depression. The investigators hypothesize that taVNS will improve depression and cortical activity in Parkinson's disease patients with depression.

Frequently Asked Questions

What is The Efficacy and Safety of Transcutaneous Auricular Vagus Nerve Stimulation for Depression in PD?

The Efficacy and Safety of Transcutaneous Auricular Vagus Nerve Stimulation for Depression in PD is a clinical trial registered under NCT07679529. Current status: NOT_YET_RECRUITING.

What is the status of NCT07679529?

The current status of NCT07679529 (The Efficacy and Safety of Transcutaneous Auricular Vagus Nerve Stimulation for Depression in PD) is: NOT_YET_RECRUITING.

When did The Efficacy and Safety of Transcutaneous Auricular Vagus Nerve Stimulation for Depression in PD start?

The Efficacy and Safety of Transcutaneous Auricular Vagus Nerve Stimulation for Depression in PD started on 2026-07-01.

Official Source

View on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.

↑